Clinical Trial Update: Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing investigational T1225 eye drops to Tobramycin 0.3% eye drops in children with purulent bacterial conjunctivitis; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Purulent Bacterial Conjunctivitis

Drugs mentioned

• T1225
• Tobramycin 0.3% Eye Drops (Tobramycin)

Snippet

Sponsor: Laboratoires Thea | Conditions: Purulent Bacterial Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2014-10-29